Skip to main content

Table 1 Demographic data of trial subjects.

From: A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

   20-40 Y 41-64 Y Total
   N = 50 N = 50 N = 100
Characteristics Parameters or
Categories
Value
or n
% Value
or n
% Value
or n
%
Age (years) Mean 31.1 - 49.6 - 40.3 -
  SD 5.69 - 6.04 - 10.89 -
  Median 31 - 49 - 40.5 -
  Minimum 20 - 41 - 20 -
  Maximum 40 - 63 - 63 -
Gender Female 25 50 32 64 57 57
  Male 25 50 18 36 43 43
Race Asian-Japanese heritage 50 100 50 100 100 100
Height (cm) Mean 165.9 - 162.5 - 164.2 -
  SD 8.41 - 7.46 - 8.1 -
  Median 164 - 161.5 - 163 -
Weight (kg) Mean 60.7 - 60.6 - 60.6 -
  SD 12.13 - 11.28 - 11.65 -
  Median 61 - 57.6 - 59 -
  1. 20-40 Y = subjects aged 20-40 years; 41-64 Y = subjects aged 41-64 years; N = total number of subjects;
  2. n/% = number/percentage of subjects in a given category; value = value of the considered parameter;
  3. SD = standard deviation